FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple NSCLC Therapies

July 12, 2017 – On June 22, the U.S. Food and Drug Administration (FDA) granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing–based test that simultaneously screens tumor samples for biomarkers associated with three FDA-approved therapies for non–small cell lung cancer (NSCLC). The Oncomine … (leggi tutto)